The week in pharma: action, reaction and insight – week to January 28, 2022

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

With the fourth-quarter financial results season starting, Johnson & Johnson, as ever, was the first big pharma to release figures on Tuesday, and these beat expectations. US biotech Incyte last Tuesday announced a clinical setback for its parsaclisib trial and decision to opt out of continued development of MCLA-145 with Mersus. Troubled US biotech Biogen has entered a deal to sell its nearly 50% stake in Samsung Bioepis, the biosimilars joint venture Samsung BioLogics, for $2.3 billion. TG Therapeutics suffered a setback with the US Food and Drug Administration putting a partial clinical hold on its study of leukemia candidate Ukoniq, but the news was more to do with how it slipped out.

J&J looks to be bolder on deals

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology